Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Apr 4

PMID 35372014

Authors

Qingfan Zheng

Bin Zhang

Changfeng Li

Xuewen Zhang

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is an aggressive tumor characterized by a poor prognosis. Therapeutic options are limited in patients with advanced stage of CCA, as a result of the intrinsic or acquired resistance to currently available chemotherapeutic agents, and the lack of new drugs entering into clinical application. The challenge in translating basic research to the clinical setting, caused by preclinical models not being able to recapitulate the tumor characteristics of the patient, seems to be an important reason for the lack of effective and specific therapies for CCA. So, there seems to be two ways to improve patient outcomes. The first one is developing the combination therapies based on a better understanding of the mechanisms contributing to the resistance to currently available chemotherapeutic agents. The second one is developing novel preclinical experimental models that better recapitulate the genetic and histopathological features of the primary tumor, facilitating the screening of new drugs for CCA patients. In this review, we discussed the evidence implicating the mechanisms underlying treatment resistance to currently investigated drugs, and the development of preclinical experiment models for CCA.

Citing Articles

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Jaidee R, Jusakul A, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A Sci Rep. 2025; 15(1):8621.

PMID: 40074934 PMC: 11904213. DOI: 10.1038/s41598-025-93192-1.

Apigenin Induces Apoptosis and Inhibits Migration in Human Cholangiocarcinoma Cells.

Kaewmanee M, Limpaiboon T, Ngernyuang N Toxics. 2025; 13(2).

PMID: 39997927 PMC: 11860412. DOI: 10.3390/toxics13020112.

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6.

Bai M, Wang R, Huang C, Zhong R, Jiang N, Fu W Sci Rep. 2024; 14(1):29661.

PMID: 39613883 PMC: 11607416. DOI: 10.1038/s41598-024-81392-0.

A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma.

Kongtanawanich K, Prasopporn S, Jamnongsong S, Thongsin N, Payungwong T, Okada S Sci Rep. 2024; 14(1):22619.

PMID: 39349745 PMC: 11442615. DOI: 10.1038/s41598-024-73581-8.

3D Modeling: Insights into the Metabolic Reprogramming of Cholangiocarcinoma Cells.

Ciufolini G, Zampieri S, Cesaroni S, Pasquale V, Bonanomi M, Gaglio D Cells. 2024; 13(18.

PMID: 39329720 PMC: 11430555. DOI: 10.3390/cells13181536.

References

Khan S, Genus T, Morement H, Murphy A, Rous B, Tataru D . Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019; 71(6):1261-1262. DOI: 10.1016/j.jhep.2019.07.024. View

Ikenoue T, Terakado Y, Nakagawa H, Hikiba Y, Fujii T, Matsubara D . A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci Rep. 2016; 6:23899. PMC: 4817147. DOI: 10.1038/srep23899. View

Hahnvajanawong C, Wattanawongdon W, Chomvarin C, Anantachoke N, Kanthawong S, Sripa B . Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. Cancer Cell Int. 2015; 14:68. PMC: 4392878. DOI: 10.1186/1475-2867-14-68. View

Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F . Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008; 15(10):730-8. DOI: 10.1038/gt.2008.39. View

Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F . Management and potentialities of primary cancer cultures in preclinical and translational studies. J Transl Med. 2017; 15(1):229. PMC: 5688825. DOI: 10.1186/s12967-017-1328-z. View

Razumilava N, Gores G . Cholangiocarcinoma. Lancet. 2014; 383(9935):2168-79. PMC: 4069226. DOI: 10.1016/S0140-6736(13)61903-0. View

Fan B, Malato Y, Calvisi D, Naqvi S, Razumilava N, Ribback S . Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122(8):2911-5. PMC: 3408746. DOI: 10.1172/JCI63212. View

Cree I, Glaysher S, Harvey A . Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010; 10(4):375-9. DOI: 10.1016/j.coph.2010.05.001. View

Sasaki H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N . Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. Br J Cancer. 2014; 111(7):1275-84. PMC: 4183840. DOI: 10.1038/bjc.2014.399. View

10.

Lobry C, Oh P, Aifantis I . Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011; 208(10):1931-5. PMC: 3182047. DOI: 10.1084/jem.20111855. View

11.

Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H . Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proc Natl Acad Sci U S A. 2017; 114(19):E3806-E3815. PMC: 5441746. DOI: 10.1073/pnas.1619416114. View

12.

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

13.

Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L . Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther. 2017; 16(4):614-624. PMC: 5539948. DOI: 10.1158/1535-7163.MCT-15-1010. View

14.

Choi J, Jo B . Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm. 2004; 280(1-2):221-7. DOI: 10.1016/j.ijpharm.2004.05.014. View

15.

Krook M, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey K . Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol Cancer Ther. 2020; 19(3):847-857. PMC: 7359896. DOI: 10.1158/1535-7163.MCT-19-0631. View

16.

Eichelbaum M, Ingelman-Sundberg M, Evans W . Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57:119-37. DOI: 10.1146/annurev.med.56.082103.104724. View

17.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni J, Cavalloni G, Migliardi G . Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010; 10:631. PMC: 3000850. DOI: 10.1186/1471-2407-10-631. View

18.

Martinez-Becerra P, Vaquero J, Romero M, Lozano E, Anadon C, Macias R . No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm. 2012; 9(6):1693-704. DOI: 10.1021/mp300028a. View

19.

Surh Y, Kundu J, Na H . Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008; 74(13):1526-39. DOI: 10.1055/s-0028-1088302. View

20.

Wu W, Zhang R, Shi X, Zhu M, Xu L, Zeng H . Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. Oncol Rep. 2014; 31(6):2515-24. DOI: 10.3892/or.2014.3123. View